TriaGen Wealth Management LLC Makes New Investment in Certara, Inc. $CERT

Key Points

• TriaGen Wealth Management LLC acquired 40,624 shares of Certara, Inc. for approximately $475,000 in the 2nd quarter, according to their 13F filing with the SEC.
• Certara's latest earnings report showed a missed EPS estimate at $0.07, below the forecast of $0.10, but a quarterly revenue increase of 12.1% year-over-year.
• Analysts have varied opinions on Certara, with price targets ranging from $15.00 to $18.00, yielding an average target of $15.50 and ratings including six buy and five hold recommendations.

TriaGen Wealth Management LLC acquired a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 40,624 shares of the company's stock, valued at approximately $475,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Private Advisor Group LLC lifted its stake in Certara by 4.0% in the first quarter. Private Advisor Group LLC now owns 24,517 shares of the company's stock valued at $243,000 after acquiring an additional 949 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Certara by 0.3% in the 1st quarter. Invesco Ltd. now owns 394,037 shares of the company's stock valued at $3,901,000 after purchasing an additional 1,285 shares during the period. B. Metzler seel. Sohn & Co. AG lifted its stake in Certara by 1.4% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 115,592 shares of the company's stock valued at $1,144,000 after purchasing an additional 1,636 shares during the last quarter. Choreo LLC lifted its stake in Certara by 4.1% in the 1st quarter. Choreo LLC now owns 52,644 shares of the company's stock valued at $521,000 after purchasing an additional 2,062 shares during the last quarter. Finally, AdvisorNet Financial Inc bought a new position in Certara during the second quarter worth about $25,000. Institutional investors own 73.96% of the company's stock.

Certara Stock Performance

CERT opened at $13.45 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.16 and a quick ratio of 2.16. The business has a fifty day simple moving average of $11.13 and a 200 day simple moving average of $11.37. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $15.69. The company has a market capitalization of $2.16 billion, a PE ratio of 269.05 and a beta of 1.45.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The firm had revenue of $104.57 million for the quarter, compared to analyst estimates of $104.14 million. Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm's quarterly revenue was up 12.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.07 EPS. Research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Insider Transactions at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the business's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider owned 73,979 shares of the company's stock, valued at $807,850.68. The trade was a 40.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the company. UBS Group dropped their price objective on Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Morgan Stanley began coverage on Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price target on the stock. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Certara in a report on Saturday, September 27th. KeyCorp decreased their price objective on shares of Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Finally, Craig Hallum began coverage on shares of Certara in a research report on Monday, September 29th. They issued a "buy" rating and a $16.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $15.50.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.